Pausing breast cancer treatment for pregnancy appears safe
A new study is reassuring for women who are taking hormone-blocking pills after a breast cancer diagnosis and want to become pregnant
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Young women diagnosed with breast cancer often must delay pregnancy for years while they take hormone-blocking pills.
A reassuring new study finds they can take a two-year break from these drugs to get pregnant without raising their short-term risk of cancer coming back.
“This is really good news for young women and their doctors and their families,” said Dr. Ann Partridge of Dana-Farber Cancer Institute in Boston, who led the study. Results were being discussed Thursday at the San Antonio Breast Cancer Symposium.
Though more common in older women, breast cancer is increasingly diagnosed during childbearing years for reasons that aren’t clear.
For patients whose cancers are fueled by hormones, treatment involves surgery, then spending five to 10 years taking either a hormone-blocking drug that can cause birth defects or newer drugs called aromatase inhibitors and a monthly shot to shut down the ovaries.
Partridge estimates 6,000 U.S. women a year want to get pregnant but must take hormone-blocking drugs.
“They don’t want to hear from breast cancer again, but they also don’t want to put their lives on hold,” she said.
The study followed 516 women after surgery for early-stage cancer. All then spent at least 18 months taking hormone-blocking drugs. The women stopped hormone-blockers for up to two years to get pregnant, deliver and breastfeed. Then they restarted cancer therapy.
After three years, about 9% saw cancer come back, similar to the rate seen in a set of similar women in a separate study who stayed on hormone-blocking therapy. There were nine deaths, “below expected rates for this population,” Partridge said.
More than 300 babies were born to women in the study. Among them was Brayden, now 4, the son of Amy Bianchi.
“He’s perfect in every way,” Bianchi said. “I couldn’t imagine my life without him. We couldn’t imagine our family without him.”
Bianchi felt a lump, which turned out to be breast cancer, when her firstborn, Mia, was 18 months old. Doctors advised against another pregnancy, but she learned of the research and signed up.
“If I had listened to the first few doctors or oncologists that I spoke with, I would have lost all my hope,” said Bianchi, 42, of Niskayuna, New York. “I would have very quickly accepted that I would never have the family that I had envisioned.”
She was able to breastfeed her son for six months before resuming hormone-blocking therapy, which she'll continue until 2026.
Researchers will follow Bianchi and the other study participants and report on the longer term safety.
“Will we see a difference at 10 years?” asked Dr. Hope Rugo of University of California, San Francisco's Comprehensive Cancer Center who was not involved in the study. “For the moment, this is incredibly encouraging data. It should give practitioners and patients confidence" as they discuss ways to benefit from cancer therapy while starting a family.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.